24
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Establishing Patient Registries for Rare Diseases: Rationale and Challenges

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Globally, an estimated 350 million people are affected by a rare disease diagnosis. Knowledge limitations persist for the majority of rare conditions due to systemic and structural challenges in healthcare and research. Disease-specific patient populations are often small and geographically dispersed; funding support for research is restricted; and diagnostic delays are common due to disease complexities, limited medical training for practitioners, and evolving foundational knowledge related to disease characterization. Patient registries can be effective, convenient, and cost-efficient tools to support documentation of the natural history of a disease, centering patients as research partners in the process while uniting rare communities around a common initiative. Current global trends towards innovative and patient-centered healthcare are enabling patient registries to increasingly emerge as valuable tools for use within rare disease research and drug development. This article describes the value of and rationale for establishing rare disease patient registries and the considerations and challenges that stakeholders, such as researchers, industry, health care providers, and patient community organizations, may encounter.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: not found
          • Article: not found

          The Challenge of Rare Diseases

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Bringing big data to personalized healthcare: a patient-centered framework.

            Faced with unsustainable costs and enormous amounts of under-utilized data, health care needs more efficient practices, research, and tools to harness the full benefits of personal health and healthcare-related data. Imagine visiting your physician's office with a list of concerns and questions. What if you could walk out the office with a personalized assessment of your health? What if you could have personalized disease management and wellness plan? These are the goals and vision of the work discussed in this paper. The timing is right for such a research direction--given the changes in health care, reimbursement, reform, meaningful use of electronic health care data, and patient-centered outcome mandate. We present the foundations of work that takes a Big Data driven approach towards personalized healthcare, and demonstrate its applicability to patient-centered outcomes, meaningful use, and reducing re-admission rates.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              From scientific discovery to treatments for rare diseases – the view from the National Center for Advancing Translational Sciences – Office of Rare Diseases Research

              We now live in a time of unprecedented opportunities to turn scientific discoveries into better treatments for the estimated 30 million people in the US living with rare diseases. Despite these scientific advances, more than 90% of rare diseases still lack an effective treatment. New data and genetics technologies have resulted in the first transformational new treatments for a handful of rare diseases. This challenges us as a society to accelerate progress so that no disease and no patient is, ultimately, left behind in getting access to safe and effective therapeutics. This article reviews initiatives of the National Center for Advancing Translational Sciences (NCATS) Office of Rare Diseases Research (ORDR) that are aimed at catalyzing rare diseases research. These initiatives fall into two groups: Promoting information sharing; and building multi-disciplinary multi-stakeholder collaborations. Among ORDR’s information sharing initiatives are GARD (The Genetics and Rare Diseases Information Center), RaDaR (The Rare Diseases Registries Program) and the NCATS Toolkit for Patient-Focused Therapy Development (Toolkit). Among the collaboration initiatives are the RDCRN (Rare Diseases Clinical Research Network), and the NCATS ORDR support for conferences and workshops. Despite the success of these programs, there remains substantial work to be done to build enhanced collaborations, clinical harmonization and interoperability, and stakeholder engagement so that the recent scientific advances can benefit all patients on the long list of rare diseases waiting for help.
                Bookmark

                Author and article information

                Contributors
                vboulanger@rarediseases.org
                mschlemmer@rarediseases.org
                srossov@rarediseases.org
                aseebald@rarediseases.org
                pgavin@rarediseases.org
                Journal
                Pharmaceut Med
                Pharmaceut Med
                Pharmaceutical Medicine
                Springer International Publishing (Cham )
                1178-2595
                1179-1993
                25 March 2020
                25 March 2020
                2020
                : 34
                : 3
                : 185-190
                Affiliations
                GRID grid.453732.4, ISNI 0000 0001 1940 1742, National Organization for Rare Disorders, ; 55 Kenosia Avenue, Danbury, CT 06810 USA
                Article
                332
                10.1007/s40290-020-00332-1
                7286934
                32215853
                fadfcd82-e1cb-402d-975c-5bd8cbf62862
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

                History
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/100000038, U.S. Food and Drug Administration;
                Award ID: U18 FD 005320
                Categories
                Leading Article
                Custom metadata
                © Springer Nature Switzerland AG 2020

                Comments

                Comment on this article